Direkt zum Inhalt
Merck

Bone marrow endosteal stem cells dictate active osteogenesis and aggressive tumorigenesis.

Nature communications (2023-05-15)
Yuki Matsushita, Jialin Liu, Angel Ka Yan Chu, Chiaki Tsutsumi-Arai, Mizuki Nagata, Yuki Arai, Wanida Ono, Kouhei Yamamoto, Thomas L Saunders, Joshua D Welch, Noriaki Ono
ZUSAMMENFASSUNG

The bone marrow contains various populations of skeletal stem cells (SSCs) in the stromal compartment, which are important regulators of bone formation. It is well-described that leptin receptor (LepR)+ perivascular stromal cells provide a major source of bone-forming osteoblasts in adult and aged bone marrow. However, the identity of SSCs in young bone marrow and how they coordinate active bone formation remains unclear. Here we show that bone marrow endosteal SSCs are defined by fibroblast growth factor receptor 3 (Fgfr3) and osteoblast-chondrocyte transitional (OCT) identities with some characteristics of bone osteoblasts and chondrocytes. These Fgfr3-creER-marked endosteal stromal cells contribute to a stem cell fraction in young stages, which is later replaced by Lepr-cre-marked stromal cells in adult stages. Further, Fgfr3+ endosteal stromal cells give rise to aggressive osteosarcoma-like lesions upon loss of p53 tumor suppressor through unregulated self-renewal and aberrant osteogenic fates. Therefore, Fgfr3+ endosteal SSCs are abundant in young bone marrow and provide a robust source of osteoblasts, contributing to both normal and aberrant osteogenesis.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
3-Isobutyl-1-methylxanthin, ≥99% (HPLC), powder
Sigma-Aldrich
Anti-Aggrecan Antibody, Chemicon®, from rabbit
Sigma-Aldrich
eSpCas9-Protein, from Streptococcus pyogenes with mutations conferring enhanced specificity, recombinant, expressed in E. coli, 1X NLS
Sigma-Aldrich
Anti-Perilipin A/B antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution